Wasatch Advisors LP Increases Position in Inspire Medical Systems, Inc. $INSP

Wasatch Advisors LP increased its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 19.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 138,603 shares of the company’s stock after acquiring an additional 22,535 shares during the quarter. Wasatch Advisors LP owned approximately 0.48% of Inspire Medical Systems worth $7,149,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Regal Partners Ltd bought a new stake in shares of Inspire Medical Systems in the third quarter worth $7,547,000. Rheos Capital Works Inc. boosted its stake in Inspire Medical Systems by 124.0% during the 4th quarter. Rheos Capital Works Inc. now owns 117,400 shares of the company’s stock valued at $10,828,000 after acquiring an additional 65,000 shares during the last quarter. Banque Pictet & Cie SA boosted its stake in Inspire Medical Systems by 797.5% during the 4th quarter. Banque Pictet & Cie SA now owns 24,474 shares of the company’s stock valued at $2,257,000 after acquiring an additional 21,747 shares during the last quarter. Aberdeen Group plc grew its holdings in Inspire Medical Systems by 16.3% during the 4th quarter. Aberdeen Group plc now owns 460,901 shares of the company’s stock worth $42,509,000 after acquiring an additional 64,561 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Inspire Medical Systems during the 3rd quarter worth $3,047,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on INSP shares. Oppenheimer restated a “market perform” rating on shares of Inspire Medical Systems in a research note on Monday, June 15th. Summit Redstone set a $39.00 price target on Inspire Medical Systems in a research note on Friday, May 22nd. Wells Fargo & Company lowered their price objective on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a report on Tuesday, May 5th. Truist Financial cut their price objective on Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating on the stock in a research note on Tuesday, May 5th. Finally, Bank of America downgraded Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a report on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Inspire Medical Systems presently has a consensus rating of “Hold” and a consensus target price of $81.05.

Inspire Medical Systems Stock Performance

Shares of NYSE:INSP opened at $45.65 on Friday. The company’s fifty day moving average is $45.52 and its two-hundred day moving average is $65.66. Inspire Medical Systems, Inc. has a 1-year low of $38.91 and a 1-year high of $147.03. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 4.63 and a beta of 0.73.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.28) by $0.38. The business had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The company’s quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Sell-side analysts expect that Inspire Medical Systems, Inc. will post 0.93 EPS for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.